Shopping Cart 0
Cart Subtotal
USD 0

Diabetic Neuropathy - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Diabetic Neuropathy-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy-Pipeline Review, H2 2018, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 10, 6, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Neuropathy-Overview 6

Diabetic Neuropathy-Therapeutics Development 7

Diabetic Neuropathy-Therapeutics Assessment 15

Diabetic Neuropathy-Companies Involved in Therapeutics Development 23

Diabetic Neuropathy-Drug Profiles 33

Diabetic Neuropathy-Dormant Projects 100

Diabetic Neuropathy-Discontinued Products 103

Diabetic Neuropathy-Product Development Milestones 104

Appendix 113


List Of Figure

List of Figures

Number of Products under Development for Diabetic Neuropathy, H2 2018 11

Number of Products under Development by Companies, H2 2018 12

Number of Products by Top 10 Targets, H2 2018 19

Number of Products by Stage and Top 10 Targets, H2 2018 19

Number of Products by Top 10 Mechanism of Actions, H2 2018 21

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 21

Number of Products by Routes of Administration, H2 2018 23

Number of Products by Stage and Routes of Administration, H2 2018 23

Number of Products by Molecule Types, H2 2018 25

Number of Products by Stage and Molecule Types, H2 2018 25


List Of Table

List of Tables

Number of Products under Development for Diabetic Neuropathy, H2 2018 11

Number of Products under Development by Companies, H2 2018 13

Number of Products under Development by Universities/Institutes, H2 2018 15

Products under Development by Companies, H2 2018 16

Products under Development by Universities/Institutes, H2 2018 18

Number of Products by Stage and Target, H2 2018 20

Number of Products by Stage and Mechanism of Action, H2 2018 22

Number of Products by Stage and Route of Administration, H2 2018 24

Number of Products by Stage and Molecule Type, H2 2018 26

Diabetic Neuropathy-Pipeline by Achelios Therapeutics Inc, H2 2018 27

Diabetic Neuropathy-Pipeline by Angelini Group, H2 2018 27

Diabetic Neuropathy-Pipeline by Applied Therapeutics Inc, H2 2018 27

Diabetic Neuropathy-Pipeline by Arena Pharmaceuticals Inc, H2 2018 28

Diabetic Neuropathy-Pipeline by Bristol-Myers Squibb Co, H2 2018 29

Diabetic Neuropathy-Pipeline by Celularity Inc, H2 2018 29

Diabetic Neuropathy-Pipeline by Commence Bio Inc, H2 2018 29

Diabetic Neuropathy-Pipeline by Grifols SA, H2 2018 30

Diabetic Neuropathy-Pipeline by Grunenthal GmbH, H2 2018 30

Diabetic Neuropathy-Pipeline by Immune Pharmaceuticals Inc, H2 2018 31

Diabetic Neuropathy-Pipeline by Kineta Inc, H2 2018 31

Diabetic Neuropathy-Pipeline by Medifron DBT Co Ltd, H2 2018 31

Diabetic Neuropathy-Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018 32

Diabetic Neuropathy-Pipeline by Neuralstem Inc, H2 2018 32

Diabetic Neuropathy-Pipeline by Omeros Corp, H2 2018 33

Diabetic Neuropathy-Pipeline by Reata Pharmaceuticals Inc, H2 2018 34

Diabetic Neuropathy-Pipeline by Relief Therapeutics Holding AG, H2 2018 34

Diabetic Neuropathy-Pipeline by Sphaera Pharma Pte Ltd, H2 2018 34

Diabetic Neuropathy-Pipeline by Syntrix Biosystems Inc, H2 2018 35

Diabetic Neuropathy-Pipeline by ViroMed Co Ltd, H2 2018 35

Diabetic Neuropathy-Pipeline by WEX Pharmaceuticals Inc, H2 2018 36

Diabetic Neuropathy-Pipeline by Yuhan Corp, H2 2018 36

Diabetic Neuropathy-Dormant Projects, H2 2018 104

Diabetic Neuropathy-Discontinued Products, H2 2018 107

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Diabetic Neuropathy Therapeutic Products under Development, Key Players in Diabetic Neuropathy Therapeutics, Diabetic Neuropathy Pipeline Overview, Diabetic Neuropathy Pipeline, Diabetic Neuropathy Pipeline Assessment


Companies

Achelios Therapeutics Inc

Angelini Group

Applied Therapeutics Inc

Arena Pharmaceuticals Inc

Bristol-Myers Squibb Co

Celularity Inc

Commence Bio Inc

Grifols SA

Grunenthal GmbH

Immune Pharmaceuticals Inc

Kineta Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Neuralstem Inc

Omeros Corp

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Sphaera Pharma Pte Ltd

Syntrix Biosystems Inc

ViroMed Co Ltd

WEX Pharmaceuticals Inc

Yuhan Corp

Diabetic Neuropathy-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy-Pipeline Review, H2 2018, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 10, 6, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Neuropathy-Overview 6

Diabetic Neuropathy-Therapeutics Development 7

Diabetic Neuropathy-Therapeutics Assessment 15

Diabetic Neuropathy-Companies Involved in Therapeutics Development 23

Diabetic Neuropathy-Drug Profiles 33

Diabetic Neuropathy-Dormant Projects 100

Diabetic Neuropathy-Discontinued Products 103

Diabetic Neuropathy-Product Development Milestones 104

Appendix 113


List Of Figure

List of Figures

Number of Products under Development for Diabetic Neuropathy, H2 2018 11

Number of Products under Development by Companies, H2 2018 12

Number of Products by Top 10 Targets, H2 2018 19

Number of Products by Stage and Top 10 Targets, H2 2018 19

Number of Products by Top 10 Mechanism of Actions, H2 2018 21

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 21

Number of Products by Routes of Administration, H2 2018 23

Number of Products by Stage and Routes of Administration, H2 2018 23

Number of Products by Molecule Types, H2 2018 25

Number of Products by Stage and Molecule Types, H2 2018 25


List Of Table

List of Tables

Number of Products under Development for Diabetic Neuropathy, H2 2018 11

Number of Products under Development by Companies, H2 2018 13

Number of Products under Development by Universities/Institutes, H2 2018 15

Products under Development by Companies, H2 2018 16

Products under Development by Universities/Institutes, H2 2018 18

Number of Products by Stage and Target, H2 2018 20

Number of Products by Stage and Mechanism of Action, H2 2018 22

Number of Products by Stage and Route of Administration, H2 2018 24

Number of Products by Stage and Molecule Type, H2 2018 26

Diabetic Neuropathy-Pipeline by Achelios Therapeutics Inc, H2 2018 27

Diabetic Neuropathy-Pipeline by Angelini Group, H2 2018 27

Diabetic Neuropathy-Pipeline by Applied Therapeutics Inc, H2 2018 27

Diabetic Neuropathy-Pipeline by Arena Pharmaceuticals Inc, H2 2018 28

Diabetic Neuropathy-Pipeline by Bristol-Myers Squibb Co, H2 2018 29

Diabetic Neuropathy-Pipeline by Celularity Inc, H2 2018 29

Diabetic Neuropathy-Pipeline by Commence Bio Inc, H2 2018 29

Diabetic Neuropathy-Pipeline by Grifols SA, H2 2018 30

Diabetic Neuropathy-Pipeline by Grunenthal GmbH, H2 2018 30

Diabetic Neuropathy-Pipeline by Immune Pharmaceuticals Inc, H2 2018 31

Diabetic Neuropathy-Pipeline by Kineta Inc, H2 2018 31

Diabetic Neuropathy-Pipeline by Medifron DBT Co Ltd, H2 2018 31

Diabetic Neuropathy-Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018 32

Diabetic Neuropathy-Pipeline by Neuralstem Inc, H2 2018 32

Diabetic Neuropathy-Pipeline by Omeros Corp, H2 2018 33

Diabetic Neuropathy-Pipeline by Reata Pharmaceuticals Inc, H2 2018 34

Diabetic Neuropathy-Pipeline by Relief Therapeutics Holding AG, H2 2018 34

Diabetic Neuropathy-Pipeline by Sphaera Pharma Pte Ltd, H2 2018 34

Diabetic Neuropathy-Pipeline by Syntrix Biosystems Inc, H2 2018 35

Diabetic Neuropathy-Pipeline by ViroMed Co Ltd, H2 2018 35

Diabetic Neuropathy-Pipeline by WEX Pharmaceuticals Inc, H2 2018 36

Diabetic Neuropathy-Pipeline by Yuhan Corp, H2 2018 36

Diabetic Neuropathy-Dormant Projects, H2 2018 104

Diabetic Neuropathy-Discontinued Products, H2 2018 107

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Diabetic Neuropathy Therapeutic Products under Development, Key Players in Diabetic Neuropathy Therapeutics, Diabetic Neuropathy Pipeline Overview, Diabetic Neuropathy Pipeline, Diabetic Neuropathy Pipeline Assessment


Companies

Achelios Therapeutics Inc

Angelini Group

Applied Therapeutics Inc

Arena Pharmaceuticals Inc

Bristol-Myers Squibb Co

Celularity Inc

Commence Bio Inc

Grifols SA

Grunenthal GmbH

Immune Pharmaceuticals Inc

Kineta Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Neuralstem Inc

Omeros Corp

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Sphaera Pharma Pte Ltd

Syntrix Biosystems Inc

ViroMed Co Ltd

WEX Pharmaceuticals Inc

Yuhan Corp

chat_bubbleLet's Chat